HC Wainwright Issues Negative Estimate for MLTX Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Analysts at HC Wainwright reduced their Q3 2026 EPS estimates for shares of MoonLake Immunotherapeutics in a research note issued to investors on Thursday, August 13th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.70) per share for the quarter, down from their prior forecast of ($0.62). HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($3.34) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics’ Q4 2026 earnings at ($0.69) EPS, FY2026 earnings at ($3.17) EPS, Q1 2027 earnings at ($0.63) EPS, Q2 2027 earnings at ($0.72) EPS, Q3 2027 earnings at ($0.76) EPS and FY2027 earnings at ($2.67) EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its earnings results on Monday, August 10th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.07.

Other equities analysts have also issued reports about the company. BTIG Research reaffirmed a “buy” rating and issued a $30.00 target price on shares of MoonLake Immunotherapeutics in a research report on Tuesday, June 9th. Needham & Company LLC lifted their price target on shares of MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a report on Friday, August 7th. Finally, Leerink Partners upped their price target on shares of MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the company an “outperform” rating in a report on Wednesday, July 1st. Ten investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, MoonLake Immunotherapeutics has an average rating of “Hold” and a consensus target price of $24.57.

MoonLake Immunotherapeutics Trading Down 0.7%

Shares of MLTX opened at $16.35 on Monday. MoonLake Immunotherapeutics has a one year low of $5.95 and a one year high of $62.75. The stock has a 50-day moving average price of $18.87 and a 200 day moving average price of $17.91. The company has a debt-to-equity ratio of 0.23, a quick ratio of 12.56 and a current ratio of 12.56. The company has a market capitalization of $1.39 billion, a P/E ratio of -4.26 and a beta of 1.06.

Insider Buying and Selling

In other news, insider Kristian Reich sold 50,000 shares of MoonLake Immunotherapeutics stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $19.43, for a total value of $971,500.00. Following the completion of the transaction, the insider owned 2,824,551 shares in the company, valued at approximately $54,881,025.93. This trade represents a 1.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Da Silva Jorge Santos sold 68,289 shares of MoonLake Immunotherapeutics stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $20.02, for a total value of $1,367,145.78. Following the completion of the transaction, the chief executive officer owned 2,774,893 shares of the company’s stock, valued at approximately $55,553,357.86. The trade was a 2.40% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 344,800 shares of company stock worth $6,820,071. 10.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Large investors have recently added to or reduced their stakes in the company. Kestra Advisory Services LLC acquired a new position in MoonLake Immunotherapeutics in the fourth quarter worth $26,000. EverSource Wealth Advisors LLC boosted its holdings in shares of MoonLake Immunotherapeutics by 221.1% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,867 shares of the company’s stock valued at $53,000 after buying an additional 1,974 shares during the period. FNY Investment Advisers LLC bought a new stake in shares of MoonLake Immunotherapeutics during the 2nd quarter valued at about $58,000. Russell Investments Group Ltd. grew its position in shares of MoonLake Immunotherapeutics by 45.4% during the 4th quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock valued at $45,000 after buying an additional 1,069 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new stake in shares of MoonLake Immunotherapeutics during the 4th quarter valued at about $47,000. 93.85% of the stock is currently owned by institutional investors.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.